Practical Geriatrics ›› 2024, Vol. 38 ›› Issue (10): 983-989.doi: 10.3969/j.issn.1003-9198.2024.10.004
Previous Articles Next Articles
Received:2024-08-15
Online:2024-10-20
Published:2024-10-22
CLC Number:
| [1] CHAUDHURI K R, SAUERBIER A, ROJO J M, et al.The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system[J]. Parkinsonism Relat Disord,2015, 21(3):287-291. [2] CHAUDHURI K R, ODIN P, ANTONINI A,et al.Parkinson’s disease: the non-motor issues[J]. Parkinsonism Relat Disord, 2011, 17(10):717-723. [3] DUNLOP B W, NEMEROFF C B.The role of dopamine in the pathophysiology of depression[J]. Arch Gen Psychiatry,2007, 64(3):327-337. [4] HEINZEL S, BERG D, GASSER T, et al.Update of the MDS research criteria for prodromal Parkinson’s disease[J]. Mov Disord, 2019, 34(10):1464-1470. [5] MACÍAS-GARCÍA P, RASHID-LÓPEZ R, CRUZ-GÓMEZ Á J, et al.Neuropsychiatric symptoms in clinically defined Parkinson’s disease: an updated review of literature[J]. Behav Neurol, 2022, 2022:1213393. [6] WEINTRAUB D, MOBERG P J, DUDA J E, et al.Recognition and treatment of depression in Parkinson’s disease[J]. J Geriatr Psychiatry Neurol,2003, 16(3):178-183. [7] CARDOSO E F, MAIA F M, FREGNI F, et al.Depression in Parkinson’s disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus[J]. Neuroimage, 2009, 47(2):467-472. [8] HEMMERLE A M, HERMAN J P, SEROOGY K B.Stress, depression and Parkinson’s disease[J]. Exp Neurol,2012, 233(1):79-86. [9] CHAUDHURI K R, SCHAPIRA A H.Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment[J]. Lancet Neurol, 2009, 8(5):464-474. [10] HONG C T, TAN S, HUANG T W.Psychotherapy for the treatment of anxiety and depression in patients with Parkinson disease: a meta-analysis of randomized controlled trials[J]. J Am Med Dir Assoc,2021, 22(11):2289-2295.e2. [11] SEPPI K, RAY CHAUDHURI K, COELHO M, et al.Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review[J]. Mov Disord, 2019, 34(2):180-198. [12] LI S, JIAO R, ZHOU X, et al.Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease: a PRISMA-compliant meta-analysis[J]. Medicine: Baltimore, 2020, 99(18):e19642. [13] WILLIAMS N R, BENTZLEY B S, SAHLEM G L, et al.Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson’s disease[J]. Acta Neurol Scand,2017, 135(4):407-411. [14] ZHANG Q, HU J, WEI L, et al.Effects of dance therapy on cognitive and mood symptoms in people with Parkinson’s disease: a systematic review and meta-analysis[J]. Complement Ther Clin Pract, 2019, 36:12-17. [15] RUTTEN S, VRIEND C, SMIT J H, et al.Bright light therapy for depression in Parkinson disease: a randomized controlled trial[J]. Neurology, 2019, 92(11):e1145-e1156. [16] SMITH K M, EYAL E, WEINTRAUB D.Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability[J]. JAMA Neurol, 2015, 72(1):88-95. [17] MURDOCH K C, LARSEN D, EDEY W, et al.The efficacy of the Strength, Hope and Resourcefulness Program for people with Parkinson’s disease (SHARP-PWP): a mixed methods study[J]. Parkinsonism Relat Disord, 2020, 70:7-12. [18] RAY CHAUDHURI K, LETA V, BANNISTER K, et al.The noradrenergic subtype of Parkinson disease: from animal models to clinical practice[J]. Nat Rev Neurol,2023, 19(6):333-345. [19] DISSANAYAKA N N, SELLBACH A, MATHESON S, et al.Anxiety disorders in Parkinson’s disease: prevalence and risk factors[J]. Mov Disord, 2010, 25(7):838-845. [20] DISSANAYAKA N N, FORBES E J, PEREPEZKO K, et al.Phenomenology of atypical anxiety disorders in Parkinson’s disease: a systematic review[J]. Am J Geriatr Psychiatry, 2022, 30(9):1026-1050. [21] SCHNEIDER R B, AUINGER P, TAROLLI C G, et al.A trial of buspirone for anxiety in Parkinson’s disease: safety and tolerability[J]. Parkinsonism Relat Disord,2020, 81:69-74. [22] MOONEN A J H, MULDERS A E P, DEFEBVRE L, et al.Cognitive behavioral therapy for anxiety in Parkinson’s disease: a randomized controlled trial[J]. Mov Disord,2021, 36(11):2539-2548. [23] WEINTRAUB D, AARSLAND D, BIUNDO R, et al.Management of psychiatric and cognitive complications in Parkinson’s disease[J]. BMJ, 2022, 379:e068718. [24] BAN M, YUE X, DOU P, et al.The effects of yoga on patients with Parkinson’s disease: a meta-analysis of randomized controlled trials[J]. Behav Neurol,2021, 2021:5582488. [25] STARKSTEIN S E, MERELLO M, JORGE R, et al.The syndromal validity and nosological position of apathy in Parkinson’s disease[J]. Mov Disord,2009, 24(8):1211-1216. [26] ISELLA V, MELZI P, GRIMALDI M, et al.Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease[J]. Mov Disord,2002, 17(2):366-371. [27] REIJNDERS J S, SCHOLTISSEN B, WEBER W E, et al.Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry[J]. Mov Disord, 2010, 25(14):2318-2325. [28] MAILLET A, MÉTÉREAU E, TREMBLAY L, et al.Serotonergic and dopaminergic lesions underlying parkinsonian neuropsychiatric signs[J]. Mov Disord,2021, 36(12):2888-2900. [29] HAUSER R A, SLAWEK J, BARONE P, et al.Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease[J]. BMC Neurol, 2016, 16:90. [30] TAKAHASHI M, TABU H, OZAKI A, et al.Antidepressants for depression, apathy, and gait instability in Parkinson’s disease: a multicenter randomized study[J]. Intern Med, 2019, 58(3):361-368. [31] MELE B, VAN S, HOLROYD-LEDUC J, et al.Diagnosis, treatment and management of apathy in Parkinson’s disease: a scoping review[J]. BMJ Open, 2020, 10(9):e037632. [32] MONTAGNESE M, VIGNANDO M, FFYTCHE D, et al.Cognitive and visual processing performance in Parkinson’s disease patients with vs without visual hallucinations: a meta-analysis[J]. Cortex, 2022, 146:161-172. [33] FORSAA E B, LARSEN J P, WENTZEL-LARSEN T, et al.A 12-year population-based study of psychosis in Parkinson disease[J]. Arch Neurol,2010, 67(8):996-1001. [34] WOLTERS E C.Intrinsic and extrinsic psychosis in Parkinson’s disease[J]. J Neurol, 2001, 248(Suppl 3):III22-III27. [35] VIGNANDO M, FFYTCHE D, LEWIS S J G, et al.Mapping brain structural differences and neuroreceptor correlates in Parkinson’s disease visual hallucinations[J]. Nat Commun, 2022, 13(1):519. [36] ZHANG S, MA Y.Emerging role of psychosis in Parkinson’s disease: from clinical relevance to molecular mechanisms[J]. World J Psychiatry, 2022, 12(9):1127-1140. [37] KITTEN A K, HALLOWELL S A, SAKLAD S R, et al.Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis[J]. Innov Clin Neurosci, 2018, 15(1/2):16-22. [38] TAMPI R R, TAMPI D J, YOUNG J J, et al.Evidence for using pimavanserin for the treatment of Parkinson’s disease psychosis[J]. World J Psychiatry, 2019, 9(3):47-54. [39] ELDER G J, COLLOBY S J, FIRBANK M J, et al.Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial[J]. Alzheimers Res Ther, 2019, 11(1):9. [40] OLANOW C W, STERN M B, SETHI K.The scientific and clinical basis for the treatment of Parkinson disease (2009)[J]. Neurology, 2009, 72(21 Suppl 4):S1-S136. [41] WEINTRAUB D, KOESTER J, POTENZA M N, et al.Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients[J]. Arch Neurol, 2010, 67(5):589-595. [42] ANTONINI A, BARONE P, BONUCCELLI U, et al.ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 2017, 88(4):317-324. [43] CORVOL J C, ARTAUD F, CORMIER-DEQUAIRE F, et al.Longitudinal analysis of impulse control disorders in Parkinson disease[J]. Neurology, 2018, 91(3):e189-e201. [44] SMITH K M, XIE S X, WEINTRAUB D.Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8):864-870. [45] YU X X, FERNANDEZ H H.Dopamine agonist withdrawal syndrome: a comprehensive review[J]. J Neurol Sci, 2017, 374:53-55. [46] PAPAY K, XIE S X, STERN M, et al.Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study[J]. Neurology, 2014, 83(9):826-833. [47] LIANG J W, SHANKER V L, GROVES M.Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study[J]. Neurology, 2015, 84(13):1386-1387. [48] ZHANG X L, WANG G B, ZHAO L Y, et al.Clonidine improved laboratory-measured decision-making performance in abstinent heroin addicts[J]. PLoS One, 2012, 7(1):e29084. [49] LAURENCIN C, TIMESTIT N, MARQUES A, et al.Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial[J]. J Neurol, 2023, 270(10):4851-4859. [50] KEHAGIA A A, HOUSDEN C R, REGENTHAL R, et al.Targeting impulsivity in Parkinson’s disease using atomoxetine[J]. Brain, 2014, 137(Pt 7):1986-1997. [51] BORCHERT R J, RITTMAN T, PASSAMONTI L, et al.Atomoxetine enhances connectivity of prefrontal networks in Parkinson’s disease[J]. Neuropsychopharmacology, 2016, 41(8):2171-2177. [52] AVERBECK B B, O’SULLIVAN S S, DJAMSHIDIAN A.Impulsive and compulsive behaviors in Parkinson’s disease[J]. Annu Rev Clin Psychol, 2014, 10:553-580. [53] OKAI D, ASKEY-JONES S, SAMUEL M, et al.Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers[J]. Neurology, 2013, 80(9):792-799. [54] BIUNDO R, WEIS L, ANTONINI A.Cognitive decline in Parkinson’s disease: the complex picture[J]. NPJ Parkinsons Dis, 2016, 2:16018. [55] GONZÁLEZ-USIGLI H A, ORTIZ G G, CHARLES-NIO C, et al.Neurocognitive psychiatric and neuropsychological alterations in Parkinson’s disease: a basic and clinical approach[J]. Brain Sci, 2023, 13(3):508. [56] ROLINSKI M, FOX C, MAIDMENT I, et al.Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease[J]. Cochrane Database Syst Rev, 2012, 2012(3):CD006504. [57] WANG H F, YU J T, TANG S W, et al.Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis[J]. J Neurol Neurosurg Psychiatry, 2015, 86(2):135-143. [58] AARSLAND D, BATZU L, HALLIDAY G M, et al.Parkinson disease-associated cognitive impairment[J]. Nat Rev Dis Primers, 2021, 7(1):47. [59] DAUWAN M, BEGEMANN M J H, SLOT M I E, et al.Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials[J]. J Neurol, 2021, 268(4):1222-1246. [60] OPHEY A, GIEHL K, REHBERG S, et al.Effects of working memory training in patients with Parkinson’s disease without cognitive impairment: a randomized controlled trial[J]. Parkinsonism Relat Disord, 2020, 72:13-22. [61] MAGGIO M G, DE COLA M C, LATELLA D, et al.What about the role of virtual reality in Parkinson disease’s cognitive rehabilitation? preliminary findings from a randomized clinical trial[J]. J Geriatr Psychiatry Neurol, 2018, 31(6):312-318. [62] CRISPO J A, WILLIS A W, THIBAULT D P, et al.Associations between anticholinergic burden and adverse health outcomes in Parkinson disease[J]. PLoS One, 2016, 11(3):e0150621. [63] EHRT U, BROICH K, LARSEN J P, et al.Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study[J]. J Neurol Neurosurg Psychiatry, 2010, 81(2):160-165. [64] MAGGI G, TROJANO L, BARONE P, et al.Sleep disorders and cognitive dysfunctions in Parkinson’s disease: a meta-analytic study[J]. Neuropsychol Rev, 2021, 31(4):643-682. |
| [1] | SUN Yi, RONG Zhe, WANG Feng, XU Chang, ZHENG Huifen. Intelligent detection and intervention of freezing of gait in Parkinson's disease [J]. Practical Geriatrics, 2024, 38(2): 123-127. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|
